Success Metrics

Clinical Success Rate
100.0%

Based on 5 completed trials

Completion Rate
100%(5/5)
Active Trials
4(33%)
Results Posted
20%(1 trials)

Phase Distribution

Ph phase_1
4
33%
Ph phase_2
8
67%

Phase Distribution

4

Early Stage

8

Mid Stage

0

Late Stage

Phase Distribution12 total trials
Phase 1Safety & dosage
4(33.3%)
Phase 2Efficacy & side effects
8(66.7%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

100.0%

5 of 5 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

4

trials recruiting

Total Trials

12

all time

Status Distribution
Active(4)
Completed(5)
Other(3)

Detailed Status

Completed5
unknown3
Active, not recruiting2
Recruiting2

Development Timeline

Analytics

Development Status

Total Trials
12
Active
4
Success Rate
100.0%
Most Advanced
Phase 2

Trials by Phase

Phase 14 (33.3%)
Phase 28 (66.7%)

Trials by Status

completed542%
active_not_recruiting217%
unknown325%
recruiting217%

Recent Activity

4 active trials
Showing 5 of 12
recruitingphase_2

The IMmunotherapy Pleural 5-ALA PDT

NCT04400539
completedphase_1

Nivolumab in Association With Radiotherapy and Cisplatin in Locally Advanced Cervical Cancers Followed by Adjuvant Nivolumab for up to 6 Months (NiCOL)

NCT03298893
active_not_recruitingphase_2

Neoadjuvant Immune Checkpoint Blockade in Resectable Malignant Pleural Mesothelioma

NCT03918252
active_not_recruitingphase_1

Evaluation of AL3818 in Combination With Nivolumab in Solid Tumors

NCT04165330
completedphase_2

Nivolumab With Chemotherapy in Pleural Mesothelioma After Surgery

NCT04177953
View all 12 trials

Clinical Trials (12)

Showing 12 of 12 trials
NCT04400539Phase 2

The IMmunotherapy Pleural 5-ALA PDT

Recruiting
NCT03298893Phase 1

Nivolumab in Association With Radiotherapy and Cisplatin in Locally Advanced Cervical Cancers Followed by Adjuvant Nivolumab for up to 6 Months (NiCOL)

Completed
NCT03918252Phase 2

Neoadjuvant Immune Checkpoint Blockade in Resectable Malignant Pleural Mesothelioma

Active Not Recruiting
NCT04165330Phase 1

Evaluation of AL3818 in Combination With Nivolumab in Solid Tumors

Active Not Recruiting
NCT04177953Phase 2

Nivolumab With Chemotherapy in Pleural Mesothelioma After Surgery

Completed
NCT03715946Phase 2

Adjuvant De-Escalated Radiation + Adjuvant Nivolumab for Intermediate-High Risk P16+ Oropharynx Cancer

Completed
NCT06008925Phase 1

Clinical Study of VG161 Combined With Nivolumab Injection in Patients With Advanced Metastatic Gastric Cancer

Recruiting
NCT03304093Phase 2

Immunotherapy by Nivolumab for HIV+ Patients

Completed
NCT03226756Phase 2

Nivolumab in Recurrent and/or Metastatic SCCHN

Completed
NCT03146468Phase 2

Nivolumab for Relapsed or Residual Haematological Malignancies After Allogeneic Stem Cell Transplantation

Unknown
NCT04021420Phase 1

Safety and Efficacy of Sonocloud Device Combined With Nivolumab in Brain Metastases From Patients With Melanoma

Unknown
NCT04343144Phase 2

Trial Evaluating Efficacy and Safety of Nivolumab (Optivo®) in Patients With COVID-19 Infection, Nested in the Corimmuno-19 Cohort.

Unknown

All 12 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
12